The establishment and validation of novel therapeutic targets to retard progression of chronic kidney disease.
Carol Pollock, Anna Zuk, Hans-Joachim Anders, Mohammad Reza Ganji, David W Johnson, Bertram Kasiske, Robyn G Langham, Roberto Pecoits-Filho, Giuseppe Remuzzi, Jerome Rossert, Yusuke Suzuki, Tetsuhiro Tanaka, Robert Walker, Chih-Wei Yang, Joseph V Bonventre
Kidney International Supplements | Published : 2017
The focus of this article is to define goals and resulting action plans that can be collectively embraced by interested stakeholders to facilitate new therapeutic approaches to mitigate chronic kidney disease progression. The specific goals include identifying druggable targets, increasing the capacity for preclinical and early clinical development, broadening the availability of new therapeutic approaches, and increasing investment in the development of new therapies to limit chronic kidney disease. Key deliverables include the establishment of new regional, national, and global consortia; development of clinical trial networks; and creation of programs to support the temporary mutual movem..View full abstract